Peptide news, explained
What changed, what it means, what’s still hype. Sourced and dated, new posts every week.
Retatrutide for Sleep Apnea: What the TRIUMPH-OSA Trials Found
Retatrutide cut sleep apnea breathing events by up to 34 per hour in two phase 3 trials in NEJM. The real numbers, the side effects and what comes next.
Read the breakdown →
Lower-Dose CagriSema: About 21% Weight Loss in REDEFINE 9
REDEFINE 9 tested CagriSema at two lower doses and found about 21% average weight loss at 68 weeks vs 2% on placebo. What it means and what is still unknown.
- Retatrutide · 39 amino acids
Retatrutide for Knee Pain: What the TRIUMPH-4 Trial Found
Retatrutide eased knee osteoarthritis pain and cut weight up to 23.7% in a phase 3 trial published in NEJM on Nov 8, 2026. The results, side effects and status.

Foundayo for Sleep Apnea: What the ATTAIN-OSA Trials Found
Lilly's Foundayo pill cut sleep apnea breathing events in two phase 3 trials published in JAMA. The real numbers, the side effects and what happens next.
- Tirzepatide · 39 amino acids
Zepbound and Foundayo on Hims & Hers: What the Lilly Deal Means
Lilly now sells Zepbound and Foundayo directly on Hims & Hers at LillyDirect prices, from $149 a month. What changed, what it costs and the fine print.
- Retatrutide · 39 amino acids
Retatrutide vs Ozempic: Head-to-Head Trial Results
Retatrutide cut weight 20.9% vs 9.4% on Ozempic in the first phase 3 head-to-head trial in type 2 diabetes. What the Oct 28 results show and what comes next.

HHS Peptide Policy: 6 Peptides Pharmacies Can Compound for Now
HHS says it will not act against licensed pharmacies compounding BPC-157, TB-500 and 4 more peptides under set conditions. What changed and what did not.

Medicare GLP-1 Bridge: How the $50 Copay Works in 2026
Medicare's GLP-1 Bridge covers Wegovy, Zepbound KwikPen and Foundayo for $50 a month through 2027. Who qualifies and what to check at open enrollment.

CagriSema in Women: 25% Weight Loss Across Menopause Stages
New REDEFINE 1 analyses show women on CagriSema lost 25% of body weight on average at 68 weeks, with strong results before, during and after menopause.

FDA Peptide Interim Access Policy: What the Oct 15 Step Means
On Oct 15, 2026 the FDA sent an interim access policy for compounding peptides like BPC-157 to the White House. What it could change, and what it cannot.

503A vs 503B Compounding: What It Means for Peptides
503A vs 503B in plain English: who can compound peptides, who needs a prescription, and why the 2026 FDA peptide vote runs through 503A.
- GHK-Cu · 3 amino acids
GHK-Cu Copper Peptide: Evidence and FDA Status in 2026
GHK-Cu has decades of lab data and only small human skin studies. What the evidence shows, topical vs injectable, and its FDA status as of October 2026.

Peptides for Recovery: What the Evidence Shows in 2026
BPC-157, TB-500, KPV, GHK-Cu and more: the evidence grade and FDA status of each recovery peptide, what is known, what is not, and the legit path in 2026.
- Tirzepatide · 39 amino acids
EloraTZP: Results for Lilly's Amylin Plus Tirzepatide Combo
EloraTZP pairs tirzepatide with the amylin peptide eloralintide. What the EASD 2026 phase 2 trial found, the side effects, and when phase 3 starts.
- Sermorelin · 29 amino acids
Sermorelin 503A Status (2026): Can Pharmacies Compound It?
Yes, with a prescription. Sermorelin is off every FDA 503A list, but its Geref history keeps it compoundable. What changed in 2026 and what it means for you.

CagriSema in 2026: New EASD Data and the FDA Decision Ahead
CagriSema pairs semaglutide with an amylin peptide. What the new EASD 2026 data showed, the trial results so far, and when an FDA decision is expected.
- Semaglutide · 31 amino acids
GLP-1 Pills in 2026: Oral Wegovy vs Foundayo, Compared
Two GLP-1 weight-loss pills are now FDA-approved. How oral Wegovy and Foundayo compare on trial results, daily routine, side effects and cash price.
- Retatrutide · 39 amino acids
Retatrutide TRIUMPH-2 Results Explained (EASD 2026)
Full TRIUMPH-2 results for retatrutide in type 2 diabetes: up to 20.8% weight loss and A1C down up to 1.6 points at 80 weeks. What the numbers mean, plainly.
- Retatrutide · 39 amino acids
Retatrutide vs Tirzepatide vs Semaglutide (2026)
Retatrutide, tirzepatide and semaglutide compared honestly: mechanism, trial weight loss, side effects, and the big difference: only two are FDA-approved today.
- Retatrutide · 39 amino acids
What Is Retatrutide? The Triple-Agonist, Explained
Retatrutide is an investigational weekly injection that acts on three hormone receptors: GIP, GLP-1 and glucagon. How it works, what trials show, its status.
- Retatrutide · 39 amino acids
When Will Retatrutide Be Available? FDA Filing Q1 2027
Not yet. Lilly plans to file with the FDA in Q1 2027, so approval likely lands in late 2027. The timeline, early access, and why research vials are not it.

CJC-1295: What the Evidence Actually Shows in 2026
CJC-1295 is a long-acting GHRH analog discussed for growth hormone support. Here is the real human trial evidence, the safety history, and its current regulatory status.

How Much Does GLP-1 Telehealth Cost in 2026? Wegovy, Zepbound & More
What semaglutide and tirzepatide actually cost via telehealth in 2026 — insured, manufacturer cash-pay programs, and bundled telehealth pricing — broken down plainly.

GLP-1 Telehealth: How Online Weight-Loss Prescriptions Work in 2026
How GLP-1 telehealth actually works in 2026 — the intake, the licensed prescriber, what gets shipped, and how it differs from a site that skips the exam entirely.
- Ipamorelin · 5 amino acids
Ipamorelin: What the Evidence Actually Shows in 2026
Ipamorelin is a selective ghrelin receptor agonist discussed for growth hormone support. Here is what human research actually shows, the gaps, and its current regulatory status.
- BPC-157 · 15 amino acids
PCAC Vote Results: 6 of 7 Peptides Recommended (BPC-157, TB-500 & More)
In July 2026 an FDA advisory committee recommended 6 of 7 peptides, including BPC-157 and TB-500, for the 503A Bulks List. Here are the votes and what comes next.
- BPC-157 · 15 amino acids
BPC-157: What the Evidence Actually Shows in 2026
BPC-157 is one of the most-discussed recovery peptides — and one of the least studied in humans. Here is the real evidence, the gaps, and its current regulatory status.
- Semaglutide · 31 amino acids
Compounded vs Brand-Name Semaglutide in 2026: What Changed
Mass compounding of semaglutide mostly ended in 2025. Here is what is still legally compounded, how brand-name pricing has shifted, and how to tell the two apart in 2026.
- BPC-157 · 15 amino acids
Is BPC-157 Legal in 2026? The Honest, Current Answer
BPC-157 is not FDA-approved and not banned outright. Here is its actual regulatory status in 2026, what changed in April, and what the July 2026 PCAC vote means.

PCAC July 2026 Review Explained: BPC-157, TB-500 & More
On July 23–24, 2026 the FDA advisory committee weighs BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon, and DSIP. Here is what the meeting can and cannot change.
- Tirzepatide · 39 amino acids
Semaglutide vs Tirzepatide: The Honest 2026 Comparison
Semaglutide vs tirzepatide, compared plainly: how they differ, what the trials show for weight loss, cost, side effects, and how to think about choosing — no hype.

TB-500: What the Evidence Actually Shows in 2026
TB-500 is discussed as a synthetic version of thymosin beta-4. Here is what human and animal research actually show, the gaps, and its current regulatory status.

FDA Peptide Reclassification 2026: The Full List of What Actually Changed
In 2026 the FDA moved 12 peptides — including BPC-157 and TB-500 — off its restricted list. Here is what changed, what did not, and what the July PCAC review means, in plain English.

Are GLP-1s Like Semaglutide Actually Peptides? (Yes — Here's How They Work)
Semaglutide and tirzepatide are the most famous molecules in medicine right now — and they are peptides. Here is what that means, how they work, and how they differ, in plain English.

How to Get Peptides Prescribed: The Legitimate Path in 2026
A step-by-step, no-hype guide to accessing peptides the legal and safe way — through a licensed provider and a compounding pharmacy — plus what things cost and the red flags to avoid.